First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies
Sandra Irenaeus(Uppsala University), Gustav Ullenhag(Uppsala University), Per Norlén(Medicon Village), Anneli Nilsson(Medicon Village), Adnan Deronic(Medicon Village), Niina Veitonmäki(Pure Biologics (Poland)), Camilla Wennersten(Medicon Village), Peter Ellmark(Lund University), Dorte Nielsen(University of Copenhagen), Jeffrey Yachnin(Karolinska University Hospital)
Cited by 142
Related Papers
Effect of Obesity on Prognosis After Early-Stage Breast Cancer
|Journal of Clinical Oncology|2010|600
Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?
|Cancer Epidemiology Biomarkers & Prevention|2006|364
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
|Cancer Treatment Reviews|2013|328
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
|Journal of Clinical Oncology|1998|285
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
|BMC Pharmacology and Toxicology|2014|264